27.83
0.06 (0.22%)
| 前收盘价格 | 27.77 |
| 收盘价格 | 27.80 |
| 成交量 | 493,511 |
| 平均成交量 (3个月) | 2,010,227 |
| 市值 | 4,415,674,880 |
| 市盈率 (P/E TTM) | 73.24 |
| 预期市盈率 (P/E Forward) | 42.92 |
| 价格/销量 (P/S) | 10.33 |
| 股市价格/股市净资产 (P/B) | 15.94 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | 10.13% |
| 营业利益率 (TTM) | 7.13% |
| 稀释每股收益 (EPS TTM) | 0.250 |
| 季度收入增长率 (YOY) | 90.40% |
| 季度盈利增长率 (YOY) | -96.60% |
| 总债务/股东权益 (D/E MRQ) | 107.29% |
| 流动比率 (MRQ) | 4.02 |
| 营业现金流 (OCF TTM) | -61.02 M |
| 杠杆自由现金流 (LFCF TTM) | -87.64 M |
| 资产报酬率 (ROA TTM) | 7.26% |
| 股东权益报酬率 (ROE TTM) | 19.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | TG Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 9.74% |
| 机构持股比例 | 63.22% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合